Ahsan Khan, MD
Psychiatry · Oklahoma City, OKNPI 1346245479
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 57.9% of the total. 2025 is the largest year on record at $2,615, more than ten times the $256 reported in 2019.
Across 118 payments — averaging $35.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Johnson & Johnson$329
- Alkermes, Inc.$253
- Teva Pharmaceuticals USA, Inc.$216
- AbbVie$210
- Vanda Pharmaceuticals Inc.$188
- plus $544 from 9 others
What the payments were for
- Travel & lodging$1,86845%
- Food & beverage$2,26555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 19 | $2,393 |
| Johnson & Johnson | 19 | $329 |
| Alkermes, Inc. | 16 | $253 |
| Teva Pharmaceuticals USA, Inc. | 13 | $216 |
| AbbVie(2 entities) | 7 | $210 |
| Vanda Pharmaceuticals Inc. | 12 | $188 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $123 |
| Indivior Inc. | 7 | $104 |
| Sunovion Pharmaceuticals Inc. | 6 | $79 |
| Boston Scientific | 3 | $79 |
| Noven Therapeutics, LLC | 3 | $49 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,132 in reported general payments places this provider in the 85th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyzine Pamoate | 12 | $107 |
| Trazodone Hcl | 12 | $39 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Oklahoma City
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
- Relindis TitaOklahoma City$6K
- Janita ArdisOklahoma City$6K
- Fiona LiOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.